Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated…
Conditions studied
Hypertension, Resistant to Conventional Therapy
About this study
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.
Interventions
- Drug: Minocycline Hydrochloride — Minocycline Hydrochloride 100 mg twice daily
- Drug: Placebo — Placebo
Primary outcomes
- 24-h systolic blood pressure (3 months)
- Gut microbiome (3 months)
- Gut inflammation and leakiness (3 months)
- Neuroinflammation (3 months)
Eligibility information
Study locations
- UF Clinical Research Center (UF CRC) - CTSI, Gainesville, Florida 32610 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.